Who Can Use MDR's Four-Year Derogation Extension? Notified Bodies Try To Clarify

Many companies are pinning hopes on being able to use the EU Medical Device Regulation's four-year extension period for products CE marked under the current directives. But with a lack of clarity from the policymakers so far, TEAM-NB has stepped in.

MT1805_Extend-Time_386315788_1200.jpg

The EU notified body association, TEAM-NB, is taking steps to help its members and their manufacturer clients better understand how to make use of the derogation for an extension to certificates delivered under the Medical Devices and Active Implantable Medical Devices Directives in the context of the wording of the new Medical Devices Regulation (MDR).

In its just released position paper, TEAM-NB is proposing a series of clauses as a template that could be...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Archive

Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

Cardiac catheter reuse targeted by FDA; lab testing of used catheters planned.

REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.

Heart valve sewing cuffs to be developed:

St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.

Nissho sales flat at only 1% in 1997:

Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.

More from Medtech Insight

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says - Clone

 
• By 

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.

US Original PMAs and Panel-Track Supplementss

 
• By 

Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.

Test Focus Of Tariff Conversations Shifts To Stability, AdvaMed Says

 
• By 

AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.